$83.33+2.38%Close 13 Nov 2026 · Market value $30.72B
About Dexcom
Dexcom is a medical device company focused on designing, developing and commercializing continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health. Its products include the Dexcom G7 and G7 15 Day CGM systems, the Dexcom ONE+ system sold in Europe, and Stelo, an over-the-counter glucose biosensor launched in the United States. The company sells to patients, caregivers and clinicians through a direct sales organization in North America and certain international markets, supplemented by distributors, and reports that most of its revenue comes from the United States. It also operates in markets across North America, Africa, Asia Pacific, Europe, Latin America and the Middle East. Its main manufacturing facilities are in Mesa, Arizona and Penang, Malaysia.
A summary of the business section of the company's latest annual report, filed 12 Feb 2026.
Company facts
| Ticker | DXCM · Nasdaq |
|---|
| Sector | Medical devices |
|---|
| Industry | Health Care Equipment |
|---|
| Index | S&P 500 |
|---|
| Fiscal year ends | 31 December |
|---|
| Reporting currency | USD |
|---|
| CIK | 1093557 |
|---|
| Latest annual report | 10-K, filed 12 Feb 2026 |
|---|
Officers and directors
| Name | Role | Shares owned | Latest Form 4 |
|---|
| Jacob Leach | President, CEO, and Director · Director | 323K · < 1% | Shares withheld for tax, 8 Nov 2026 |
|---|
| Kevin Sayer | Executive Chair · Director | 302K · < 1% | Sale under a 10b5-1 plan, 20 Aug 2026 |
|---|
| Steven Altman | Director | 63.7K · < 1% | Grant or award, 28 May 2026 |
|---|
| Jereme Sylvain | EVP, COO & CFO | 63.3K · < 1% | Shares withheld for tax, 8 Nov 2026 |
|---|
| Mark Foletta | Director | 56.9K · < 1% | Sale under a 10b5-1 plan, 3 Aug 2026 |
|---|
| Sadie Stern | EVP Chief People & Culture Off | 56.8K · < 1% | Shares withheld for tax, 8 Nov 2026 |
|---|
| Richard Collins | Director | 40.2K · < 1% | Grant or award, 28 May 2026 |
|---|
| Nicholas Augustinos | Director | 38.5K · < 1% | Sale under a 10b5-1 plan, 15 Sep 2026 |
|---|
| Michael Brown | EVP Chief Legal Compliance Off | 38.2K · < 1% | Shares withheld for tax, 8 Nov 2026 |
|---|
| Bridgette Heller | Director | 26.0K · < 1% | Sale under a 10b5-1 plan, 12 Aug 2026 |
|---|
| Kyle Malady | Director | 22.7K · < 1% | Grant or award, 28 May 2026 |
|---|
| Jon Coleman | EVP, Chief Commercial Officer | 17.2K · < 1% | Sale under a 10b5-1 plan, 4 Jun 2026 |
|---|
| Rimma Driscoll | Director | 10.4K · < 1% | Grant or award, 28 May 2026 |
|---|
| Dr. Euan Ashley | Director | 0 · < 1% | Gift, 30 Oct 2026 |
|---|
| Boehnlein Glenn S | Director | — | Grant or award, 10 Sep 2026 |
|---|
| Osterloh Albert Frederick IV | Director | — | Grant or award, 28 May 2026 |
|---|
| GALA RENEE D | Director | — | Grant or award, 28 May 2026 |
|---|
| Dahut Karen M | Director | — | Gift, 8 May 2025 |
|---|
| TOPOL ERIC | Director | — | Gift, 8 May 2025 |
|---|
| Dolan Matthew Vincent | EVP, Strategy & Corporate Dev | — | Open-market sale, 29 Jan 2025 |
|---|
Holdings as the latest proxy statement states them, all forms counted; the latest Form 4 line each filed. People appointed since the proxy are listed from their Form 4 filings.
DXCM in the terminal
The business section of every annual report, officers' holdings and trades, and the company's filings as they arrive.